Skip to main content

Table 4 Comparison between groups with and without PEP

From: Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial

Characteristics

Patients with post-ERCP pancreatitis (N = 21 )

Patients without post-ERCP pancreatitis

(N = 145)

P

Female

17

93

0.14

Male

4

52

Age (years)

48.3 ± 16.2

53.7 ± 18.3

0.21

 <50 years

11

63

0.44

 >50 years

10

82

Ambulatory ERCP

10

81

0.51

Hospitalized ERCP

11

64

Dilated bile duct by imaging studies pre-ERCP

14

104

0.58

Without dilation bile duct by imaging studies pre-ERCP

7

41

Diameter of the bile duct by ERCP (mm)

9.0 ± 2.1

11.9 ± 5.0

0.001

With previous cholecystectomy

13

69

0.12

Without previous cholecystectomy

8

76

Elevated pre-ERCP bilirubin

18

99

0.12

Normal pre-ERCP bilirubin

3

46

Number of attempts to cannulate the biliary tract

9.1 ± 2.7

7.1 ± 3.5

0.02

Difficult cannulation

   

 <8 attempts

5

83

0.005

 >8 attempts

16

62

Precut (access) sphincterotomy

   

 Yes

17

78

0.01

 No

4

67

Biliary sphincterotomy

   

 Yes

11

86

0.54

 No

10

59

Cannulation time of the bile duct (min)

8.7 ± 2.8

6.1 ± 3.5

0.001

ERCP Length (min)

30.0 ± 3.7

23.7 ± 7.2

0.001

Pancreatography

   

 Yes

17

62

0.002

 No

4

83

Number of passes of the guide in the Wirsung duct.

2.3 ± 0.76

1.40 ± 0.75

0.000

Number of injections into the Wirsung duct.

2.0 ± 0.72

1.43 ± 0.64

0.001

Pancreatography extension

   

 Partial

2

9

0.39

 Full

13

52

 Acinarization

2

1

 Serum amylase at 2 hours post-ERCP (U/L)

1163.5 ± 999.6

176.9 ± 105.2

0.001